$59.02
7.42% yesterday
Nasdaq, Jul 29, 10:15 pm CET
ISIN
CH0334081137
Symbol
CRSP

CRISPR Therapeutics AG Stock price

$59.02
+10.38 21.34% 1M
+17.81 43.22% 6M
+19.66 49.95% YTD
+0.52 0.89% 1Y
-15.98 21.31% 3Y
-26.51 31.00% 5Y
+44.93 318.88% 10Y
+44.93 318.88% 20Y
Nasdaq, Closing price Tue, Jul 29 2025
-4.73 7.42%
ISIN
CH0334081137
Symbol
CRSP
Industry

Key metrics

Basic
Market capitalization
$5.5b
Enterprise Value
$3.7b
Net debt
positive
Cash
$1.9b
Shares outstanding
86.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
146.1 | 115.0
EV/Sales
96.9 | 76.2
EV/FCF
negative
P/B
3.0
Financial Health
Equity Ratio
86.2%
Return on Equity
-19.0%
ROCE
-23.2%
ROIC
-163.3%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$37.7m | $47.9m
EBITDA
$-455.2m | $-507.8m
EBIT
$-474.4m | $-535.6m
Net Income
$-385.7m | $-477.2m
Free Cash Flow
$-307.9m
Growth (TTM | estimate)
Revenue
-86.1% | 28.3%
EBITDA
-63.2% | -13.5%
EBIT
-58.9% | -14.8%
Net Income
-77.6% | -30.3%
Free Cash Flow
-82.2%
Margin (TTM | estimate)
Gross
-
EBITDA
-1,208.3% | -1,060.6%
EBIT
-1,259.2%
Net
-1,023.6% | -996.8%
Free Cash Flow
-817.1%
More
EPS
$-4.5
FCF per Share
$-3.6
Short interest
33.3%
Employees
393
Rev per Employee
$90.0k
Show more

Is CRISPR Therapeutics AG a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

CRISPR Therapeutics AG Stock Analysis

Unlock Scores for Free

Analyst Opinions

35 Analysts have issued a CRISPR Therapeutics AG forecast:

22x Buy
63%
12x Hold
34%
1x Sell
3%

Analyst Opinions

35 Analysts have issued a CRISPR Therapeutics AG forecast:

Buy
63%
Hold
34%
Sell
3%

Financial data from CRISPR Therapeutics AG

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
38 38
86% 86%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 195 195
6% 6%
518%
- Research and Development Expense 317 317
13% 13%
841%
-455 -455
63% 63%
-1,208%
- Depreciation and Amortization 19 19
2% 2%
51%
EBIT (Operating Income) EBIT -474 -474
59% 59%
-1,259%
Net Profit -386 -386
78% 78%
-1,024%

In millions USD.

Don't miss a Thing! We will send you all news about CRISPR Therapeutics AG directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

CRISPR Therapeutics AG Stock News

Neutral
The Motley Fool
about 17 hours ago
Biotechnology outfit CRISPR Therapeutics (CRSP -1.37%) isn't a name on many investors' radar -- and understandably so. Its market capitalization is a mere $6 billion.
Positive
Seeking Alpha
6 days ago
Crispr Therapeutics AG stock has surged nearly 90% since my Buy call in early May, reaching its highest value since February 2024. The rally builds on the historic approval of Casgevy, a gene editing therapy for Sickle Cell Disease, developed with Vertex. Earlier concerns over slow Casgevy sales and lengthy patient hospital stays weighed heavily on the stock, which hit a five-year low in April.
Positive
24/7 Wall Street
7 days ago
Insider buying has been slow this month, as buy windows close ahead of the new earnings-reporting season.
More CRISPR Therapeutics AG News

Company Profile

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.

Head office Switzerland
CEO Samarth Kulkarni
Employees 393
Founded 2013
Website crisprtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today